^(18)PDG PET/CT评价利妥昔单抗联合CHOP方案治疗9例弥漫大B细胞淋巴瘤的疗效  

^(18)PDG PET/CT in Evaluating the Therapeutic Response of 9 Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab Combined with CHOP Regimen

作　　者：赵鸿鹰 王宇[1,2,3] 赵鸿雁[1,2,3] 徐建军 江荣科[1,2,3] 

机构地区：[1]黑龙江省大庆市油田总院集团龙南医院 [2]齐齐哈尔医学院附属第五医院 [3]黑龙江省大庆市油田总院,大庆163000

出　　处：《中国医疗器械信息》2008年第6期80-81,83,共3页China Medical Device Information

摘　　要：目的:探讨18F标记的2-脱氧葡萄糖正电子发射断层显像技术(18PDG PET/CT)在接受R-CHOP方案(利妥昔单抗+环磷酰胺、阿霉素、长春新碱和强的松)治疗的弥漫大B细胞淋巴瘤(DLBCL)患者疗效评价中的价值。方法:回顾了我院2005.5-2007.5月收治的9例接受了R-CHOP方案治疗且接受了PET/CT评价的DLBCL患者的临床资料,分析PET/CT对这9例患者在治疗过程中的疗效评价情况,以及对治疗的指导价值。结论:PET/CT比常规方法更有能准确、有效地对DLBCL患者的治疗效果进行评价,对DLBCL进一步治疗的决策及患者的预后判断有重要的价值。Objective： To investigate the clinical value of 18F fluorodeoxyglucose （FDG） PET in evaluating the therapeutic response of patients with diffuse large B cell lymphoma（DLBCL） treated with R-CHOP regimen （Rituximab combined with cyclophosphamide, adriamyein,vincr-stine and prednisone）. Methods We had reviewed the clinicai documents of 9 patients diagnosed as DLBCL and treated in our hospital between 2005.5 and 2007.5, receiving R-CHOP regimen and PET/CT evaluation., and made a analysis of PET/CT in evaluating the therapeutic response of these 9 patients in the process of treatment, and its value of guiding further treatment. Conclusion： PET/CT is able to evaluate patients＇ response to treatment more accurately and effectively than traditional methods, and of great significance in making further treatment strategies and predicting prognosis for patients with DLBCL.

关 键 词：体层摄影术 发射型计算机 单光子 非霍奇金淋巴瘤 利妥昔单抗 环磷酰胺 阿霉素 长春新碱强的松 疗效评价 

分 类 号：R815[医药卫生—放射医学]